Texas A&M AgriLife researchers uncovered a promising target for controlling gene expression and other cellular processes, ...

Researchers have identified unique RNA structures called G-quadruplexes (G4s) that promote harmful α-synuclein protein ...

B.Riley Financial analyst Madison Elsaadi has reiterated their bullish stance on WVE stock, giving a Buy rating on October 31. Madison Elsaadi ...

Synthetic genes, though few, can generate complex biomolecular materials when their expression is part of a temporal control ...

Australian scientists have successfully used an innovative gene therapy technique in the lab to combat a key cause of vision ...

Like humans and other complex multicellular organisms, single-celled bacteria can fall ill and fight off viral infections. A ...

Neuroblastoma (NB), the most prevalent extracranial solid tumor in children, poses a significant therapeutic challenge due to ...

HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its investigational new drug (IND) application for HG202, the world's first ...

HG202 is the first-ever clinical-stage CRISPR/Cas13 RNA-editing and the only clinical-stage RNA-targeting therapy for nAMD. “This open IND for HG202 by the US FDA – the first regulator to have cleared ...

In this Thought Leader article., Ian Johnston from Cytiva discusses challenges related to process development, scaling technology, regulatory approvals, and GMP guidelines.

Neuroblastoma (NB), the most prevalent extracranial solid tumor in children, poses a significant therapeutic challenge due to ...

A study from Kumamoto University reveals that G-quadruplex RNA structures facilitate the aggregation of α-synuclein, a ...